Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Nov 19, 2021 1:56pm
217 Views
Post# 34146859

RE:RE:RE:RE:RE:Mugs

RE:RE:RE:RE:RE:MugsJust do me a favour Stockings ... just accept me for being a guy who likes this company and who has doubled down over the last while.  I'm not asking you to buy shares nor do I care if you buy shares.

I am more than open to being challenged here but calling me a "pumper" doesn't help our go-forward relationship.

Can you do that for me ?

-----------------------------------

Liver confusion is what we're seeing as OTENA is being used in the body for a longer period of time.  As OTENA produces H2S, the liver is eventually getting confused because it's used to making it's own H2S.  Eventually it stops producing because it's confused (maybe saturated).  That's the idea for what's happening right now with the liver enzymes.  The goal is to figure out how to provide enough painkiller and just the right amount of H2S in order to keep the liver happy making its own H2S without thinking it needs to stop due to this saturation.

That's why OTENA seems perfect for acute (short duration doesn't seem to confuse the liver) and due to the higher potency (than expected) of the drug.

What we learn from OTENA on the acute side will help on the chronic side - as going lower for chronic won't work - but - maybe bursts of higher dosing in a different regimen makes more sense for chronic purposes.

That's the way I see it.
<< Previous
Bullboard Posts
Next >>